Clinical Trials
111 trialsNCT05181462 2026-05-27
TRIFOUR
Cantargia AB
Phase 1/2 Completed
NCT04417088 2026-03-20
Exablate Blood-Brain Barrier Disruption for the Treatment of rGBM in Subjects Undergoing Carboplatin Monotherapy
InSightec
Phase 1/2 Completed
NCT04440358 2026-01-20
Exablate Blood-Brain Barrier Disruption With Carboplatin for the Treatment of rGBM
InSightec
Phase 1/2 Completed
NCT05664971 2025-12-02
JS004 Combined With Toripalimab and With Standard Chemotherapy Treat Patients With Advanced Lung Cancer
Shanghai Junshi Bioscience Co., Ltd.
Phase 1/2 Completed
NCT02227199 2025-11-18
BV-ICE
University of Washington
Phase 1/2 Completed
NCT05459129 2025-09-15
A Study Evaluating Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Morpheus-Head and Neck Cancer)
Hoffmann-La Roche
Phase 1/2 Completed
NCT02730546 2025-06-22
Pembrolizumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Adult Patients With Locally Advanced Gastroesophageal Junction or Gastric Cardia Cancer That Can Be Removed by Surgery
Mayo Clinic
Phase 1/2 Completed
NCT06087289 2025-06-08
KANDOVA
Novakand Pharma AB
Phase 1/2 Completed
NCT02713386 2025-05-25
Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NRG Oncology
Phase 1/2 Completed
NCT01458366 2025-04-30
Phase I/II Study of Bendamustine in Combination With Ofatumumab, Carboplatin and Etoposide
Thomas Jefferson University
Phase 1/2 Completed
NCT02098343 2025-03-17
p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246
Aprea Therapeutics
Phase 1/2 Completed
NCT03267316 2024-08-22
CANFOUR
Cantargia AB
Phase 1/2 Completed
NCT03490292 2024-07-26
Avelumab With Chemoradiation for Stage II/III Resectable Esophageal and Gastroesophageal Cancer
University of Wisconsin, Madison
Phase 1/2 Completed
NCT01837862 2024-07-05
A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas
Northwell Health
Phase 1/2 Completed
NCT02606305 2024-06-14
Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer
ImmunoGen, Inc.
Phase 1/2 Completed
NCT02348216 2024-06-04
ZUMA-1
Gilead Sciences
Phase 1/2 Completed
NCT03126812 2024-05-29
Neo-adjuvant Pembrolizumab in Primary Stage IV Ovarian Cancer
The Netherlands Cancer Institute
Phase 1/2 Completed
NCT04647344 2024-04-25
A Study of AK104 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
Akeso
Phase 1/2 Completed
NCT02735239 2024-03-22
Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer
Ludwig Institute for Cancer Research
Phase 1/2 Completed
NCT03853707 2024-02-20
Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Treating Patients With Metastatic Triple Negative Breast Cancer
City of Hope Medical Center
Phase 1/2 Completed
NCT02567799 2024-01-25
NSCLC
Humanetics Corporation
Phase 1/2 Completed
NCT01402271 2023-12-11
Pazopanib Hydrochloride, Paclitaxel, and Carboplatin in Treating Patients With Refractory or Resistant Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Phase 1/2 Completed
NCT02018861 2023-09-28
A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101)
Incyte Corporation
Phase 1/2 Completed
NCT01705158 2023-09-06
MYCA
ARCAGY/ GINECO GROUP
Phase 1/2 Completed
NCT03840915 2023-08-21
M7824 in Combination With Chemotherapy in Stage IV Non-small Cell Lung Cancer (NSCLC)
EMD Serono
Phase 1/2 Completed
NCT01618136 2023-06-18
An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors
Eisai Inc.
Phase 1/2 Completed
NCT01711541 2023-06-07
Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IV Head and Neck Cancer
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT01004731 2023-05-25
Study of Anti-Epidermal Growth Factor Receptor (EGFr) Antibody, Cetuximab, in Combination With Gemcitabine/Carboplatin in Patients With Stage IV Lung Cancer
University of Alabama at Birmingham
Phase 1/2 Completed
NCT03577704 2023-04-12
HLX07Ib/II
Shanghai Henlius Biotech
Phase 1/2 Completed
NCT00453154 2023-04-04
Cisplatin or Carboplatin, and Etoposide With or Without Sunitinib Malate in Treating Patients With Extensive-Stage Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT02983045 2023-03-13
PIVOT-02
Nektar Therapeutics
Phase 1/2 Completed
NCT03366480 2023-02-22
Endolung
Ability Pharmaceuticals SL
Phase 1/2 Completed
NCT01982955 2022-11-08
Tepotinib With Gefitinib in Participants With Locally Advanced or Metastatic NSCLC (INSIGHT)
Merck KGaA, Darmstadt, Germany
Phase 1/2 Completed
NCT02039674 2022-11-08
MK-3475-021
Merck Sharp & Dohme LLC
Phase 1/2 Completed
NCT03085914 2022-09-23
A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Participants With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)
Incyte Corporation
Phase 1/2 Completed
NCT03744026 2022-09-07
SC9-GBM-01
CarThera
Phase 1/2 Completed
NCT03029598 2022-07-26
Pembrolizumab and Carboplatin in Treating Patients With Relapsed or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
University of Washington
Phase 1/2 Completed
NCT03562871 2022-04-21
IO102 With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment of Metastatic NSCLC
IO Biotech
Phase 1/2 Completed
NCT00303849 2022-03-17
Carboplatin, Melphalan, Etoposide Phosphate, Mannitol, and Sodium Thiosulfate in Treating Patients With Previously Treated Brain Tumors
OHSU Knight Cancer Institute
Phase 1/2 Completed
NCT02686346 2021-12-07
BV-ICE
The Lymphoma Academic Research Organisation
Phase 1/2 Completed
NCT03394885 2021-08-12
AdORN
Duke University
Phase 1/2 Completed
NCT01505868 2021-07-30
Cabazitaxel With or Without Carboplatin in Treating Patients With Previously Treated Metastatic Castration-Resistant Prostate Cancer
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT02941523 2021-06-02
Safety, PK and Efficacy of NOX66 as a Monotherapy and Combined With Carboplatin in Refractory Solid Tumours
Noxopharm Limited
Phase 1/2 Completed
NCT03892421 2021-05-18
Outpatient Administration of R-DHAP in Relapsed/Refractory Non-Hodgkin Lymphoma
La Raza Medical Center
Phase 1/2 Completed
NCT02574078 2021-05-06
CheckMate370
Bristol-Myers Squibb
Phase 1/2 Completed
NCT01289353 2021-01-12
Concurrent Adjuvant Carboplatin and Accelerated Radiotherapy for Triple Negative Breast Cancer
NYU Langone Health
Phase 1/2 Completed
NCT01169636 2021-01-06
Panobinostat Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Compared With ICE For Relapsed Hodgkin Lymphoma
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT03480750 2020-11-10
Trientine
National Cheng-Kung University Hospital
Phase 1/2 Completed
NCT02499770 2020-08-21
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Etoposide and Carboplatin in Extensive Stage Small Cell Lung Cancer (SCLC)
G1 Therapeutics, Inc.
Phase 1/2 Completed
NCT00278148 2020-07-20
Erlotinib, Paclitaxel, and Carboplatin Combined With Radiation Therapy for Stage III Non-Small Cell Lung Cancer
Case Comprehensive Cancer Center
Phase 1/2 Completed